Abstract
We report a case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy 6 years after primary treatment of triple-negative breast cancer. The primary tumor was negative for HER-2 as determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) (1+, and ratio, 1.1), but examination of the recurrent lymph node metastasis showed positivity for HER-2 by FISH (ratio, 5.2). No lesions were detected in either her left breast or in other organs, and the patient was diagnosed as having HER-2-positive recurrent disease. Combination chemotherapy using weekly paclitaxel and trastuzumab was initiated, and a clinically complete response was achieved. This report suggests the benefit of routine evaluation of HER-2 status in recurrent breast cancer with the introduction of HER-2-targeting agents.
MeSH terms
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor / metabolism
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / pathology
-
Carcinoma, Ductal, Breast / drug therapy*
-
Carcinoma, Ductal, Breast / metabolism
-
Carcinoma, Ductal, Breast / pathology
-
Female
-
Humans
-
In Situ Hybridization, Fluorescence
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Recurrence, Local / metabolism
-
Neoplasm Recurrence, Local / pathology
-
Paclitaxel / administration & dosage
-
Receptor, ErbB-2 / genetics
-
Receptor, ErbB-2 / metabolism*
-
Receptors, Estrogen / metabolism*
-
Receptors, Progesterone / metabolism*
-
Remission Induction
-
Trastuzumab
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Biomarkers, Tumor
-
Receptors, Estrogen
-
Receptors, Progesterone
-
ERBB2 protein, human
-
Receptor, ErbB-2
-
Trastuzumab
-
Paclitaxel